Seattle, WA 6/25/13; Washington, DC 6/25/13—NanoString Technology shares debuted on the NASDAQ Global Market under the symbol NSTG on June 26 (see IBO 5/31/13). The company listed 5.4 million shares at a price of $10 per share. NanoString expects to raise net proceeds of $46.9 million. The company also granted underwriters a 30-day option to purchase up to an additional 810,000 shares to cover over-allotments. NanoString expects to raise a total of $54.5 million if this option is exercised. The net proceeds are to be used as follows: $20 million to commercialize the Prosigna test for risk of breast cancer recurrence following regulatory approval, including the addition of an oncology sales force; $10 million to expand the clinical utility of Prosigna and to develop other diagnostic products; $5 million to expand life sciences commercial operations; $5 million to develop new life sciences applications, chemistry and instrumentation; and the remainder for working capital and general corporate purposes.